Moxibustion for COVID-19: a systematic scoping review

Moxibustion has been widely used in the prevention and treatment of COVID-19. However, there is no systematic review of current topics and clinical findings on moxibustion for COVID-19. We conducted this scoping review to systematically summarize and analyze the themes and findings of published articles, and to provide an overview of current knowledge and practice of moxibustion for COVID-19. METHODS: PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, SinoMed, Wan Fang Data, and VIP databases were searched from inception until April 2022. The relevant data were presented through bar graphs, structured tables, and figures along with descriptive statistics and analysis. This scoping review was conducted based on the PRISMA-ScR Checklist. RESULTS: A total of 76 articles were reviewed: 47 reviews, 19 clinical research studies, seven systematic reviews (all were protocols), and three guidelines. All the studies were conducted by Chinese researchers and published from January 1, 2020 to March 14, 2022. The feasibility of moxibustion in the prevention and treatment of mild or moderate COVID-19 is based on the consensus of therapeutic mechanisms and effectiveness. The most adopted approach was the suspended and gentle moxibustion, and the most frequently applied or recommended acupoints were found to be ST36, CV8, CV6, CV4, CV12, GV14, BL13, LI4, ST25, and LR3. CONCLUSIONS: As a convenient and safe traditional Chinese medicine (TCM) therapy with its specific feature, moxibustion has been significantly effective at ameliorating mild or moderate symptoms among COVID-19 patients. Further large-scale, well-designed research and international cooperation are still warranted in clinical evaluations of moxibustion. GRAPHICAL ABSTRACT: http://links.lww.com/AHM/A35.